Tags

Type your tag names separated by a space and hit enter

The economic burden of diagnosed opioid abuse among commercially insured individuals.
Postgrad Med. 2014 Jul; 126(4):53-8.PM

Abstract

The abuse of prescription opioids imposes a substantial public health and economic burden. Recent research using administrative claims data has substantiated the prevalence and cost of opioid abuse among commercially insured individuals. Although administrative claims data are readily available and have been used to effectively answer research questions about the burden of illness for many different conditions, an important issue is the reliability, replicability, and generalizability of estimates derived from different databases. Therefore, this study sought to assess whether the findings of a recently published study of opioid abuse in a commercial claims database (original analysis) could be replicated in a different commercial claims database. The original analysis, which analyzed the prevalence and excess health care costs of diagnosed opioid abuse in the OptumHealth Reporting and Insights Database, was replicated by applying the same approach to the Truven MarketScan Commercial Claims and Encounters Database (replication analysis). In the replication analysis, the prevalence of diagnosed opioid abuse increased steadily from 15.8 diagnosed opioid abusers per 10,000 in 2009, to 26.6 diagnosed opioid abusers per 10,000 in 2012. Although the prevalence of diagnosed opioid abuse was higher than reported in the original analysis, the trend of increasing prevalence over time was consistent across analyses. Additionally, diagnosed abusers had excess annual per patient health care costs of $11,376 in the replication analysis, which was consistent with the excess annual per patient health care costs of diagnosed abuse of $10,627 reported in the original analysis. The replication analysis also found an upward trend in the prevalence of diagnosed opioid abuse over time and substantial excess annual per patient health care costs of diagnosed opioid abuse among commercially insured individuals, suggesting that these findings are generalizable to other commercially insured populations.

Authors+Show Affiliations

Manager, Analysis Group, Inc., Boston, MA. brad.rice@analysisgroup.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25141243

Citation

Rice, J Bradford, et al. "The Economic Burden of Diagnosed Opioid Abuse Among Commercially Insured Individuals." Postgraduate Medicine, vol. 126, no. 4, 2014, pp. 53-8.
Rice JB, Kirson NY, Shei A, et al. The economic burden of diagnosed opioid abuse among commercially insured individuals. Postgrad Med. 2014;126(4):53-8.
Rice, J. B., Kirson, N. Y., Shei, A., Enloe, C. J., Cummings, A. K., Birnbaum, H. G., Holly, P., & Ben-Joseph, R. (2014). The economic burden of diagnosed opioid abuse among commercially insured individuals. Postgraduate Medicine, 126(4), 53-8. https://doi.org/10.3810/pgm.2014.07.2783
Rice JB, et al. The Economic Burden of Diagnosed Opioid Abuse Among Commercially Insured Individuals. Postgrad Med. 2014;126(4):53-8. PubMed PMID: 25141243.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The economic burden of diagnosed opioid abuse among commercially insured individuals. AU - Rice,J Bradford, AU - Kirson,Noam Y, AU - Shei,Amie, AU - Enloe,Caroline J, AU - Cummings,Alice Kate, AU - Birnbaum,Howard G, AU - Holly,Pamela, AU - Ben-Joseph,Rami, PY - 2014/8/21/entrez PY - 2014/8/21/pubmed PY - 2014/10/22/medline SP - 53 EP - 8 JF - Postgraduate medicine JO - Postgrad Med VL - 126 IS - 4 N2 - The abuse of prescription opioids imposes a substantial public health and economic burden. Recent research using administrative claims data has substantiated the prevalence and cost of opioid abuse among commercially insured individuals. Although administrative claims data are readily available and have been used to effectively answer research questions about the burden of illness for many different conditions, an important issue is the reliability, replicability, and generalizability of estimates derived from different databases. Therefore, this study sought to assess whether the findings of a recently published study of opioid abuse in a commercial claims database (original analysis) could be replicated in a different commercial claims database. The original analysis, which analyzed the prevalence and excess health care costs of diagnosed opioid abuse in the OptumHealth Reporting and Insights Database, was replicated by applying the same approach to the Truven MarketScan Commercial Claims and Encounters Database (replication analysis). In the replication analysis, the prevalence of diagnosed opioid abuse increased steadily from 15.8 diagnosed opioid abusers per 10,000 in 2009, to 26.6 diagnosed opioid abusers per 10,000 in 2012. Although the prevalence of diagnosed opioid abuse was higher than reported in the original analysis, the trend of increasing prevalence over time was consistent across analyses. Additionally, diagnosed abusers had excess annual per patient health care costs of $11,376 in the replication analysis, which was consistent with the excess annual per patient health care costs of diagnosed abuse of $10,627 reported in the original analysis. The replication analysis also found an upward trend in the prevalence of diagnosed opioid abuse over time and substantial excess annual per patient health care costs of diagnosed opioid abuse among commercially insured individuals, suggesting that these findings are generalizable to other commercially insured populations. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/25141243/The_economic_burden_of_diagnosed_opioid_abuse_among_commercially_insured_individuals_ L2 - https://www.tandfonline.com/doi/full/10.3810/pgm.2014.07.2783 DB - PRIME DP - Unbound Medicine ER -